

DAFTAR PUSTAKA

1. Pelcovits A, Niroula R. Acute myeloid leukemia: A review. *R I Med J*. 2020;103(3):38-40.
2. Kaushansky K, Lictman M, Prchal J LM, Press O, Burns L et al. *Williams Hematology*. 9th Edition. 9th ed. New York : McGrawHill; 2016. p. 1373-14.
3. Bagus IM, Wibawa C, Subawa AAN, Putu IW, Yasa S, Mahartini NN. Gambaran karakteristik pasien acute mieloid leukemia di RSUP Sanglah Denpasar tahun 2018. *J Med Udayana*. 2021;10(6):38-45.
4. Novotech. *Acute Myeloid Leukemia landscape in Asia-Pacific 2021*. The Asia Pasific; 2021.
5. Irawan C, Steven R , Gunarsa RG, Tenggara JB. Outcome result of acute myeloid leukemia undergoing treatment in semi-isolation chemotherapy ward. *J Penyakit Dalam Indones*. 2022;9(3):155-163.
6. Yuliana. Perkembangan terapi leukemia mieloid akut. *Cdk-250*. 2017;44(3):216-220.
7. Rahmadin B, Wahid I, Yaswir R. Profil penderita leukemia mieloblastik akut di bagian penyakit dalam RSUP dr. M. Djamil Padang. *J Kesehat Andalas*. 2018;6(3):495.
8. WHO. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. *World Heal Organ*. 2011:1-6.
9. Kar AS. Pengaruh anemia pada kanker terhadap kualitas hidup dan hasil pengobatan. *Arch Repos* . 2005;17:4-17
10. Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer : a systematic review of the literature. *Am J Med*. 2004;116(7):11-26.
11. Marsà A, Ascanio M, Diaz-García J, Darbà J. Epidemiology, management, and economic impact of acute myeloid leukemia and myelodysplastic syndrome in Spain at the hospital level: a claims database analysis. *J Med Econ*. 2020;23(12):1477-1484.
12. NCCN. *Guideline for patient : Acute Myeloid Leukemia*. 2022. <https://www.nccn.org/patientresources/patient-resources/guidelines-for-patients>
13. NCCN. *NCCN guideline : acute myeloid leukemia*. 2021:1-10.
14. Maurillo L, Bassan R, Cascavilla N, Ciceri F. Quality of response in acute myeloid leukemia: The role of minimal residual disease. *Cancers (Basel)*. 2019;11(10):1-15.

15. Shireen I, Komal S, Ansari AM, Meraj L. Frequency of complete remission after standard 3+7 induction therapy in patients with acute myeloid leukemia. *Pak J Med Sci.* 2022;38(5):1138-114
16. Nilsson M, Hallner A, Brune M, Nilsson S, Thoren FB, Marter A. Complete remission after the first cycle of induction chemotherapy determines the clinical efficacy of relapse- preventive immunotherapy in acute myeloid leukaemia. *Br J Haematol.* 2020; 188(4):49-53.
17. Ernita D. Gambaran respon kemoterapi pada lansia dengan leukemia mieloid akut di RSUP Dr. M Djamil Padang. Padang: Univ Andalas.; 2018.
18. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. *Blood.* 2017;129(4):424-447.
19. Hastuti TS, Sumantri R, Wijaya I. Complete remission of acute myeloid leukemia in induction and consolidation chemotherapy without bone marrow transplantation: lessons learned from good presentation case. *Maj Kedokt Bandung.* 2019;51(1):31-38.
20. Rouli N, Amalia P, Pediatri S. Anemia pada penyakit keganasan anak. *176 Sari Pediatr.* 2005;6(4):176-181.
21. Liem EF, Mantik M, Rampengan N, et al. Hubungan kadar hemoglobin dan tercapainya remisi pada anak penderita leukemia akut. *J Med dan Rehabil.* 2019;1(3):1-7.
22. Amalia C, Hanggara DM. Hubungan profil hematologi terhadap peluang remisi komplit pada anak leukemia mieloblastik akut. *CHMK Heal J.* 2021;5(1):269-273.
23. Jahic A, Iljazovic E, Hasic S, Arnautovic AC, Sabitovic D, Mesanovic S et al. Prognostic parameters of acute myeloid leukaemia at presentation. *Med Arch.* 2017;71(1):20-24.
24. Liersch R, Müller-Tidow C, Berdel WE, Krug U. Prognostic factors for acute myeloid leukaemia in adults - biological significance and clinical use. *Br J Haematol.* 2014;165(1):17-38.
25. hoffbrand, A.V. Paul AHM. Kapita selekta hematologi. (7,ed.). buku kedokteran EGC; 2017. p. 141-50
26. Nix NM, Price A. Acute myeloid leukemia: an ever-changing disease. *J Adv Pract Oncol.* 201;10(4):4-8.
27. National Cancer Institute (2022). Acute myeloid leukemia. NCI United State. <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/acute-myeloid-leukemia> - Diakses Juli 2022.

28. Kohrt HEK, Jezdic S. Acute myeloblastic leukaemia: a guide for patient. *Eur Soc Med Oncol*. 2011(2):1-20.
29. American Cancer Society. Acute myeloid leukemia early detection, diagnosis, and types. *Am Can Soc*. 2018:1-21.
30. Chennamadhavuni A, Lyengar VSA, Mukkamalla SKR (2022). Leukemia. StatPearl NCBI. <https://www.ncbi.nlm.nih.gov/books/NBK560490/>. Diakses Mei 2022
31. American Cancer Society. Acute myeloid leukemia causes, risk factors, and prevention .<https://www.cancer.org/cancer/acute-myeloid-leukemia/causes-risks-prevention>. Diakses April 2022
32. Zjablovskaja P, Florian MC. Acute myeloid leukemia: aging and epigenetics. *Cancers (Basel)*. 2020;12(1):1-18.
33. Momparler RL. Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia. *Exp Hematol Oncol*. 2013;2(1):1.
34. Katzung BG, Masters SB, Trevor AJ. Basic and clinical pharmacology. 14th ed. New York : McGraw-Hill;2014. p. 948-66
35. Gong Q, Zhou L, Xu S, Li X, Zou Y, Chen J. High doses of daunorubicin during induction therapy of newly diagnosed acute myeloid leukemia: A systematic review and meta-analysis of prospective clinical trials. *PLoS One*. 2015;10(5):1-14.
36. BC Cancer Drug (2019). Idarubicin. http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Idarubicin_monograph.pdf. Diakses Juli 2022.
37. Seiter K, Besa EC, editors . Acute myeloid leukemia (AML) treatment & management. <https://emedicine.medscape.com/article/197802-treatment>. Diakses Mei 2022.
38. Bittencourt R, Bortolheiro TC, Chauffaille M, Fgundes EM, Pagnano KBB, Rego EM, et al. Guidelines on the treatment of acute myeloid leukemia: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Project guidelines: Associação Médica Brasileira - 2015. *Rev Bras Hematol Hemoter*. 2016;38(1):58-74.
39. O'Donnell M, Tallman M, Abboud CN, Altman JK, Appelbaum FR, Arber D, et al. NCCN guidelines 2014 panel members acute myeloid leukemia. *Natl Compr Can Netw*. 2014;2:1-45
40. NCCN. Clinical practice guidelines in oncology : acute myeloid leukemia. Accessed. <http://www.nccn.ir/Guidelines/Summary/aml.html>. Diakses Januari 2023

41. Derber C, Estey E, Pleyer L, et al. Blood reviews time to repeal and replace response criteria for acute myeloid leukemia ?. *Blood Rev.* 2018;32:416-425.
42. Thol F. Treatment of relapsed acute myeloid leukemia. *Curr Treat Options Oncol.* 2020;3:1-11.
43. Bhargava, B. Consensus document for management of acute myeloid leukemia (AML). *Indian Counc Med Res.* 2019;13-68.
44. Zhu Y qian, Wang F, Wu X, Chen B an. Factors Influencing the prognosis of acute myeloid leukemia. *Clin Oncol Re.* 2021;4(12):10-13.
45. Camila M. Chaparro PSS. Anemia epidemiology, pathophysiology, and etiology in low- and middle-income countries. *Physiol Behav.* 2019;176(3):139-148.
46. Bakta I. *Hematologi klinik ringkas.* Jakarta : EGC; 2006. p. 19-20.
47. Kemenkes RI. *Riset Kesehatan Dasar 2013.* Jakarta : Riskesdas. 2013;7(5):803-809.
48. Kemenkes RI. *Pedoman penanggulangan anemia pada remaja putri dan wanita usia subur.* Jakarta : Kemenkes. 2018
49. Bohlius J, Weingart O, Trelle S, Engert A. Cancer-related anemia and recombinant human erythropoietin — an updated overview. *Nat Clin Pract Oncol.* 2006;3(3):152-164.
50. Van B. What is the value of hemoglobin as a prognostic and predictive factor in cancer?. *Eur J Cancer, Suppl.* 2004;2(2):11-19.
51. Sativa SO. Pengaruh genetik, gaya hidup dan lingkungan pada kejadian leukemia mieloblastik akut. *J Ilm Mahasiswa Ked Indones.* 2020;8(1):83-88.
52. Xu P, Wang M, Jiang Y, Ouyang J, Chen B. The association between expression of hypoxia inducible factor-1 α and multi-drug resistance of acute myeloid leukemia. *Transl Cancer Res.* 2017;6(1):198-205.
53. Eckardt JN, Röllig C, Metzeler K, Kramer M, Stasik S, Georgi JA, et al. Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learning. *Haematologica.* 2023;108(3):690-704.
54. Kumar M, Gaur V, Chowdhry M, Makroo RN, Sharma P. Hemoglobin level and karyotype status are independent prognostic parameters for acute myeloid leukemia: Pilot Study of 244 Patients. *Int J Med Res Heal Sci.* 2019;8(6):135-142.
55. Purwanto DAP, Mulatsih SRI, Triyono T. Faktor yang memengaruhi episode transfusi. *Indones J Cancer.* 2017;11(2):49-54.

56. Ahadiyanto. Diktat psikologi perkembangan dewasa dan lanjut usia. Jember: Univ IAIN. 2021.
57. Yu C, Kong QL, Zhang YX, et al. Clinical significance of day 5 peripheral blast clearance rate in the evaluation of early treatment response and prognosis of patients with acute myeloid leukemia. *J Hematol Oncol.* 2015;8(1):2-9.
58. Philip C, George B, Ganapule A, Korula A, Jit P, Alex AA, et al. Acute myeloid leukaemia: challenges and real world data from India. *Br J Haematol.* 2015;170(1):110-117.
59. Huang HH, Chen CM, Wang CY, Hsu WWY, Ko Bs, Chen HM, et al. The epidemiology, treatment patterns, healthcare utilizations and costs of acute myeloid leukaemia (AML) in Taiwan. *PLoS One.* 2022;17(1):1-13.
60. Han K, Id Y, Kim HJ, Min YH, Hong DS, Lee WS, et al. Age and remission induction therapy for acute myeloid leukemia : An analysis of data from the Korean acute myeloid leukemia registry. *PLoS One.* 2021;16(5):1-14.
61. Abuelgasim KA, Albuhayri B, Munshi R, Mugairi AA, Alahmari B, Gmati G, et al. Leukemia research reports impact of age and induction therapy on outcome of 180 adult patients with acute myeloid leukemia ; retrospective analysis and literature review. *Leuk Res Rep.* 2020;14(9):1-6.
62. Harystha M. Gambaran karakteristik pasien leukemia mieloblastik akut yang dirawat di bagian ilmu penyakit dalam RSUP Dr M Djamil Padang. Padang : Univ Andalas; 2016.
63. Kosasih AS, Setiawan L, Hartini SRI, Kresno SB. Immunophenotyping in the diagnosis and classification of acute leukemia: dharmais cancer hospital experience. *Indones J Cancer.* 2011;5(1):3-8.
64. Govedarovic N, Marjanovic G. Frequency and prognostic impact of FLT3/ITD mutation in patients with acute myeloid leukaemia. *J BUON.* 2011;16(1):108-111.
65. Albrecht TA, Boyiadzis M, Elswick RK, Starkweather ARM. Symptom management and psychosocial needs of adults with acute myeloid leukemia during induction treatment: a pilot study. *Cancer Nurs.* 2018;40(6):1-18.
66. Juliusson G, Jädersten M, Deneberg S, Lehmann S, Mollgard L, Wennstrom L, et al. The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting. *Blood Adv.* 2020;4(6):1094-1101.
67. Matteuzzi T, Dall'Olio D, Sträng E, Merlotti A, EliceGUI J, Benner A, et al. Impact of gender on molecular AML subclasses - a harmony alliance study. *Blood.* 2021;138(1):3438-3438.

68. Acharya UH, Halpern AB, Wu Q, Voutsinas JM, Walter RB, Yun S, et al. Impact of region of diagnosis, ethnicity, age, and gender on survival in acute myeloid leukemia (AML). *J Drug Assess.* 2018;7(1):51-53.
69. Valk PJM, Engen C, Grob T. Sex disparity in acute myeloid leukaemia with FLT3 internal tandem duplication mutations: implications for prognosis. *Mol Oncol.* 2021(15);15:2285-2299.
70. Badan Pusat Statistik. Jumlah perokok di indonesia. Statistics Indonesia. <https://www.bps.go.id/indicator/30/1533/1/persentase-merokok-pada-penduduk-usia-18-tahun-menurut-jenis-kelamin.html>. Diakses Maret 2023
71. Metayer C, Petridou E, Manuel J, Roman E, Schuz J, Magnani C, et al. Systematic reviews and meta- and pooled analyses parental tobacco smoking and acute myeloid leukemia The childhood leukemia international consortium. *Am J Epidemiol.* 2016;184(4):261-273.
72. Mahmood H, Abdullah WZ, Yong AC, Ahmed SA, Abdullah AD, Baba AA, et al. A review of AML classification: a single institution experience in a developing country. *J Hematop.* 2014;7(1):3-8.
73. Abuhelwa Z, Shaer Q Al, Taha S, Ayoub K, Amer R. Characteristics of De Novo Acute Myeloid Leukemia Patients in Palestine : Experience of An-Najah National University Hospital. *Asian Pac J Cancer Prev.* 2017;18:2459-2464.
74. Walter RB, Othus M, Burnett AK, Lowenberg B, Kantarjan HM, Ossenkoppele GJ, et al. Significance of FAB subclassification of “acute myeloid leukemia , NOS ” in the 2008 WHO classification: analysis of 5848 newly diagnosed patients. *Blood.* 2013;121(13):2424-2431.
75. Allahyari A, Tajeri T, Sadeghi M. Prognostic factors and survival in acute myeloid leukemia cases : a report from the northeast of Iran. *Asian Pac J Cancer Prev.* 2016;17:1547-1551.
76. Iqbal Z, Absar M, Shammas M, Alanazi N, Basit S, Aljarrah K, et al. Frequencies and clinical characteristics of common fusion oncogenes in core-binding factor Acute Myeloid Leukemia from Lahore Pakistan. *Adv Life Sci.* 2021;8(4):387-395.
77. Yu J, Li Y, Zhang D, Wan D, Jiang Z. Clinical implications of recurrent gene mutations in acute myeloid leukemia. *Exp Hematol Oncol.* 2020;9(4):1-11.
78. Buckley SA, Jimenez-Sahagun D, Othus M, Walter RB, Lee SJ. Quality of life from the perspective of the patient with acute myeloid leukemia. *Cancer.* 2018;124(1):145-152.
79. Asif N, Hassan K. Original article clinical manifestations of acute myeloid leukemia. *J Islamabad Med Dent Coll.* 2010;1211(1):6-9.

80. Shoket N, Muzamil J, Zargar TB, Wani B, Toka V, Bhat J, et al. Clinical profile of acute myeloid leukemia in North India and utility of nontransplant measures in its management. *Indian J Med Paediatr Oncol.* 2019;40(5):S44-S53.
81. Lacourt TE, Kavelaars A, Ohanian M, Shah ND, Shelburne SA, Futreal A, et al. Patient – reported fatigue prior to treatment is prognostic of survival in patients with acute myeloid leukemia Sample description. *Oncotarget.* 2018;9(58):31244-31252.
82. Regina D, C SR, Rao R, Regina D. Correlation of pallor with hemoglobin levels and clinical profile of anemia in primary and middle school children of rural Telangana. *Int Contemp Paediatr.* 2016;3(3):872-877.
83. Chang F, Shamsi TS, Waryah AM. Thromboembolic diseases clinical and hematological profile of acute myeloid leukemia (AML) patients of Sindh. *J Hematol Dis.* 2016;4(2): 2-5.
84. Jalaikhoo H, Mohammad S, Kashfi H, Azimzadeh P, Narimani A. Acute myeloid leukemia as the main cause of pancytopenia in iranian population. *Iran J Pathol.* 2017;12(3):265-271.
85. Sultan S, Zaheer HA, Irfan SM, Ashar S. Demographic and clinical characteristics of adult acute myeloid leukemia - tertiary care experience. *Asian Pacific J Cancer Prev.* 2016;17(1):357-360.
86. Irawan C, Steven R, Gunarsa RG, Tenggara JB. Luaran hasil leukemia mieloid akut yang menjalani terapi pada ruang kemoterapi semi-isolasi. *J Penyakit Dalam Indonesia.* 2022;9(3):155.
87. Diederich M, Morceau F, Dicato M. Pro-inflammatory cytokine-mediated anemia: regarding molecular mechanisms of erythropoiesis. *Mediators Inflamm.* 2009;2009(17):1-11.
88. Su F, Cao L, Ren X, et al. Age and sex trend differences in hemoglobin levels in China : a cross - sectional study. *BMC Endocr Disord.* 2023;3(1):4-9.
89. Hadisantoso DW, Ranuhardy D, Rajabto W, et al. Association of leukocyte nadir with complete remission in Indonesian acute myeloid leukemia patients undergoing 7+3 remission induction chemotherapy. *F1000Res.* 2022;11:1-19.
90. Udupa MS, Babu KG, Babu MC, Lakshmaiah KC, Lokanathan D, Lokesh KN, et al. Clinical profiles , cytogenetics and treatment outcomes of adult acute myeloid leukemia. *J Can Res Ther.* 2020:18-22.
91. Horibata S, Gui G, Lack J, Destefano CB, Gottesman MM. Heterogeneity in refractory acute myeloid leukemia. *Proc Natl Acad Sci USA.* 2019; 116(21):10494-10503.

92. Iqbal A, Daniel NR, Reddy R, Hazarika M, Deka R. Outcomes of induction therapy in patients with acute myeloid leukemia during the COVID-19 pandemic: a retrospective study from a tertiary cancer center. *Cureus*. 2022;14(10):1-12.
93. Stephanie. Hubungan Status Hematologi sebagai Faktor Prognostik dengan Masa Remisi Pada Pasien Anak Leukemia Limfoblastik Akut (LLA) di RSUP. H. Adam Malik dari Tahun 2009-2014. Medan : Univ Sumatera Utara;2014.
94. Tewuh S, Mantik MFJ, Warouw SM. Hubungan kadar hemoglobin dengan peluang remisi pada anak penderita leukemia limfoblastik akut periode 2010-2014 di RSUP Prof. Dr. R. D. Kandou Manado. *e-CliniC*. 2016;4(2):2014-2017.
95. Petit C, Gouel F, Dubus I, Heuclin C, Roget K, Vannier JP. Hypoxia promotes chemoresistance in acute lymphoblastic leukemia cell lines by modulating death signaling pathways. *BMC Cancer*. 2016;16(1):1-17.
96. Cassier PA, Castets M, Belhabri A, Vey N. Targeting apoptosis in acute myeloid leukaemia. *Br J Cancer*. 2017;117(8):1089-1098.
97. Deynoux M, Sunter N, Héroult O, Mazurier F. Hypoxia and hypoxia-inducible factors in leukemias. *Front Oncol*. 2016;6(41):1-9.
98. Winters R, Winters A, Amedee R. Statistics : a brief overview. *Oschsner J*. 2010;10(3):213-2016.

